GLP-1 drugs have been billed as the long-awaited panacea for the obesity pandemic that continues to ravage an ever-increasing segment of the global population. However, a new study published today has shed fresh limelight on the limitations associated with relying solely on pharmaceutical interventions to achieve an ideal BMI. Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger. Novo Nordisk sells its Semaglutide GLP-1 drugs under the Ozempic and Wegovy labels. Eli Lilly and Company, on the other hand, sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels. These drugs stimulate the release of insulin in […]
Read full article at https://wccftech.com/life-long-commitment-a-new-study-says-that-over-half-of-the-weight-lost-through-glp-1-drugs-such-as-zepbound-comes-back-after-quitting/
WccftechContinue reading/original-link]